DE68912232D1 - Konjugate zytotoxischer Arzneimittel. - Google Patents

Konjugate zytotoxischer Arzneimittel.

Info

Publication number
DE68912232D1
DE68912232D1 DE89307916T DE68912232T DE68912232D1 DE 68912232 D1 DE68912232 D1 DE 68912232D1 DE 89307916 T DE89307916 T DE 89307916T DE 68912232 T DE68912232 T DE 68912232T DE 68912232 D1 DE68912232 D1 DE 68912232D1
Authority
DE
Germany
Prior art keywords
drug conjugates
cytotoxic drug
cytotoxic
conjugates
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE89307916T
Other languages
English (en)
Other versions
DE68912232T2 (de
Inventor
David Arthur Johnson
Bennett Coleman Laguzza
William Leonard Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE68912232D1 publication Critical patent/DE68912232D1/de
Publication of DE68912232T2 publication Critical patent/DE68912232T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE68912232T 1988-08-08 1989-08-03 Konjugate zytotoxischer Arzneimittel. Expired - Fee Related DE68912232T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/229,941 US5028697A (en) 1988-08-08 1988-08-08 Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers

Publications (2)

Publication Number Publication Date
DE68912232D1 true DE68912232D1 (de) 1994-02-24
DE68912232T2 DE68912232T2 (de) 1994-05-19

Family

ID=22863313

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68912232T Expired - Fee Related DE68912232T2 (de) 1988-08-08 1989-08-03 Konjugate zytotoxischer Arzneimittel.

Country Status (14)

Country Link
US (1) US5028697A (de)
EP (1) EP0354729B1 (de)
JP (1) JPH02256700A (de)
KR (1) KR900002803A (de)
CN (1) CN1040204A (de)
AU (1) AU619328B2 (de)
DE (1) DE68912232T2 (de)
DK (1) DK382889A (de)
HU (1) HU208161B (de)
IL (1) IL91181A0 (de)
MX (1) MX165003B (de)
NZ (1) NZ230199A (de)
PT (1) PT91371B (de)
ZA (1) ZA895909B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010176A (en) * 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
ZA914625B (en) * 1990-06-22 1993-02-24 Lilly Co Eli In vivo targeting with bifunctional antibodies
US5272253A (en) * 1991-07-01 1993-12-21 Eli Lilly And Company Cluster conjugates of drugs with antibodies
GR1001459B (el) * 1992-10-08 1993-12-30 Lilly Co Eli Σύμπλεγμα συζυγών φαρμάκων με αντισώματα.
US5382582A (en) * 1993-03-26 1995-01-17 Chan; Carcy L. Methotrexate analogs and methods of using same
US5556623A (en) * 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
JPH072895A (ja) * 1993-04-28 1995-01-06 Eli Lilly & Co 抗体−薬物複合体
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
EP1355672A2 (de) 2000-12-01 2003-10-29 Cell Works Inc. "konjugate von glykosylierten/galaktosylierten peptiden, bifunktionellen linkern und nukleotid?monomeren/polymeren, damit zusammenhängende zusammensetzungen, sowie verfahren zu ihrer verwendung"
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1392359B2 (de) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Spezifische bindungsproteine und ihre verwendung
ATE512674T1 (de) * 2003-01-06 2011-07-15 Angiochem Inc Angiopep-1, verwandte verbindungen, und deren verwnedungen
US20080312201A1 (en) * 2004-09-10 2008-12-18 Patrick Fogarty Reduced Toxicity Methotrexate Formulations and Methods for Using the Same
ES2383901T5 (es) * 2005-02-18 2015-02-25 Angiochem Inc. Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
EP2233156B1 (de) 2005-07-15 2013-05-01 Angiochem Inc. Verwendung von Aprotinin-Polypeptiden als Träger in pharmazeutischen Konjugaten
JP2009517402A (ja) 2005-11-28 2009-04-30 ディー． ロウェ，バーノン 腎毒性の低減に有用な組成物及びその使用方法
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
US9023356B2 (en) 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
ES2609915T3 (es) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
CA2729613C (en) 2008-03-03 2017-02-07 Tosk, Incorporated Methotrexate adjuvants to reduce toxicity and methods for using the same
ES2721148T3 (es) * 2008-04-18 2019-07-29 Angiochem Inc Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel y métodos relacionados de preparación y uso
CN102245636A (zh) 2008-10-15 2011-11-16 安吉奥开米公司 用于药物递送的依托泊苷和多柔比星结合物
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
AU2009322043A1 (en) * 2008-12-05 2011-07-07 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
AU2009327267A1 (en) 2008-12-17 2011-07-14 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
EP2421562B1 (de) 2009-04-20 2019-03-13 Angiochem Inc. Behandlung von ovarialkarzinom mit einem an ein angiopep-2-analogon konjugierten antitumorwirkstoff
CN102596993A (zh) 2009-07-02 2012-07-18 安吉奥开米公司 多聚体肽结合物以及其应用
UA117556C2 (uk) 2011-05-16 2018-08-27 Джензайм Корпорейшн Спосіб збільшення ефективності терапевтичного засобу шляхом введення метотрексату
JP6431038B2 (ja) 2013-03-15 2018-11-28 ザイムワークス インコーポレイティド 細胞毒性及び抗有糸分裂性化合物とその使用方法
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
HUE057768T2 (hu) 2014-09-17 2022-06-28 Zymeworks Inc Citotoxikus és antimitotikus vegyületek és azok alkalmazásának módszerei
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI820020L (fi) * 1981-01-12 1982-07-13 Lilly Industries Ltd Immunoglobulinkonjugater
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
EP0083367A1 (de) * 1981-07-02 1983-07-13 WALTON, Alan G. Glykosaminglykan arzneimittelkomplexe
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
DK167884A (da) * 1983-03-30 1984-10-01 Lilly Industries Ltd Immunoglobulinkonjugater
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
GB8610551D0 (en) * 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
CA1330378C (en) * 1986-05-08 1994-06-21 Daniel J. Coughlin Amine derivatives of folic acid analogs
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US5030719A (en) * 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
IE63869B1 (en) * 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
US4918165A (en) * 1987-07-16 1990-04-17 Ophthalmic Research Corporation Mitotic inhibitor and method for preventing posterior lens capsule opacification after extracapsular extraction

Also Published As

Publication number Publication date
HU208161B (en) 1993-08-30
NZ230199A (en) 1991-09-25
PT91371A (pt) 1990-03-08
IL91181A0 (en) 1990-03-19
DK382889A (da) 1990-02-09
AU619328B2 (en) 1992-01-23
JPH02256700A (ja) 1990-10-17
HUT50850A (en) 1990-03-28
EP0354729A2 (de) 1990-02-14
PT91371B (pt) 1995-05-04
KR900002803A (ko) 1990-03-23
EP0354729B1 (de) 1994-01-12
US5028697A (en) 1991-07-02
DE68912232T2 (de) 1994-05-19
EP0354729A3 (de) 1991-04-17
AU3933889A (en) 1990-02-08
DK382889D0 (da) 1989-08-04
MX165003B (es) 1992-10-13
ZA895909B (en) 1991-04-24
CN1040204A (zh) 1990-03-07

Similar Documents

Publication Publication Date Title
DE68912232D1 (de) Konjugate zytotoxischer Arzneimittel.
DE69018647D1 (de) Arzneimittel.
DE69115229D1 (de) Arzneimittel.
DE68911473D1 (de) Arzneimittelformulierungen.
DE68901417D1 (de) Pharmazeutische zusammensetzung.
DE69101931D1 (de) Pharmazeutische Zusammensetzung.
ATE163539T1 (de) Arzneimittel
NO912799L (no) Foradditiver for droevtyggere.
AU619329B2 (en) Cytotoxic drug conjugates
MX9203602A (es) Administracion iontoforetica mejorada de farmacos.
DE69115263D1 (de) Pharmazeutische zusammensetzungen.
FI893643A0 (fi) Farmaceutiska kompositioner.
NO892764D0 (no) Medikamentell administreringsform for droevtyggere.
FI905236A0 (fi) Deoxiribonukleosider innehaollande farmaceutiska konsistenser foer laekning av saor.
DE68907392D1 (de) Dysmnesie modifizierende arzneimittel.
DE68915203D1 (de) Pharmazeutische Mischungen.
FI923371A0 (fi) En farmaceutisk formulation.
EP0299057A4 (de) Verstärkung von zytotoxischen konjugaten.
DE58905160D1 (de) Pharmazeutische zubereitung.
DE68907609D1 (de) Arzneimittelzusammensetzung.
DE69012950D1 (de) Antikrebsmittel.
DE3887237D1 (de) Arzneimittel.
DE68908838D1 (de) Pharmazeutisch wirksame Dithioketen-Derivaten.
ATE100315T1 (de) Arzneimittel.
IT8922215A0 (it) Formulazioni farmaceutiche.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee